PE20170691A1 - Composiciones farmaceuticas de accion prolongada - Google Patents

Composiciones farmaceuticas de accion prolongada

Info

Publication number: PE20170691A1
Authority: PE; Peru
Prior art keywords: compound; long; formula; acting pharmaceutical; pharmaceutical compositions
Prior art date: 2014-09-26

Application number

PE2017000515A

Other languages

English (en)

Spanish (es)

Inventor

Brian Alvin Johns

Original Assignee

Glaxosmithkline Intellectual Property (No 2) Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2014-09-26

Filing date

2015-09-24

Publication date

2017-06-13

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=54256799&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20170691(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2015-09-24 Application filed by Glaxosmithkline Intellectual Property (No 2) Ltd filed Critical Glaxosmithkline Intellectual Property (No 2) Ltd

2017-06-13 Publication of PE20170691A1 publication Critical patent/PE20170691A1/es

Links

239000008194 pharmaceutical composition Substances 0.000 title abstract 2
241000725303 Human immunodeficiency virus Species 0.000 abstract 2
150000001875 compounds Chemical class 0.000 abstract 2
-1 fatty acid esters Chemical class 0.000 abstract 2
239000004094 surface-active agent Substances 0.000 abstract 2
OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 abstract 1
229920002134 Carboxymethyl cellulose Polymers 0.000 abstract 1
229920001214 Polysorbate 60 Polymers 0.000 abstract 1
239000000337 buffer salt Substances 0.000 abstract 1
229910052791 calcium Inorganic materials 0.000 abstract 1
239000011575 calcium Substances 0.000 abstract 1
239000001768 carboxy methyl cellulose Substances 0.000 abstract 1
235000010948 carboxy methyl cellulose Nutrition 0.000 abstract 1
239000008112 carboxymethyl-cellulose Substances 0.000 abstract 1
235000014113 dietary fatty acids Nutrition 0.000 abstract 1
LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 abstract 1
239000000194 fatty acid Substances 0.000 abstract 1
229930195729 fatty acid Natural products 0.000 abstract 1
208000015181 infectious disease Diseases 0.000 abstract 1
239000002953 phosphate buffered saline Substances 0.000 abstract 1
229920001983 poloxamer Polymers 0.000 abstract 1
229920001223 polyethylene glycol Polymers 0.000 abstract 1
230000002265 prevention Effects 0.000 abstract 1
239000000243 solution Substances 0.000 abstract 1
239000003381 stabilizer Substances 0.000 abstract 1
LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poly(lactide-co-glycolide)
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Epidemiology (AREA)
Engineering & Computer Science (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Oil, Petroleum & Natural Gas (AREA)
Dermatology (AREA)
Dispersion Chemistry (AREA)
Molecular Biology (AREA)
Organic Chemistry (AREA)
Virology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Biochemistry (AREA)
AIDS & HIV (AREA)
Oncology (AREA)
Communicable Diseases (AREA)
Tropical Medicine & Parasitology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicinal Preparation (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

PE2017000515A 2014-09-26 2015-09-24 Composiciones farmaceuticas de accion prolongada PE20170691A1 (es)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US201462055779P	2014-09-26	2014-09-26
PCT/IB2015/057360 WO2016046786A1 (en)	2014-09-26	2015-09-24	Long acting pharmaceutical compositions

Publications (1)

Publication Number	Publication Date
PE20170691A1 true PE20170691A1 (es)	2017-06-13

Family

ID=54256799

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
PE2017000515A PE20170691A1 (es)	2014-09-26	2015-09-24	Composiciones farmaceuticas de accion prolongada

Country Status (18)

Country	Link
US (1)	US10092523B2 (2)
EP (1)	EP3197430A1 (2)
JP (1)	JP2017528497A (2)
KR (1)	KR20170056702A (2)
CN (1)	CN106999425A (2)
AU (1)	AU2015323321A1 (2)
BR (1)	BR112017006005A2 (2)
CA (1)	CA2961528A1 (2)
CL (1)	CL2017000714A1 (2)
CR (1)	CR20170113A (2)
DO (1)	DOP2017000086A (2)
EA (1)	EA201790495A1 (2)
IL (1)	IL251337A0 (2)
MX (1)	MX2017003928A (2)
PE (1)	PE20170691A1 (2)
SG (1)	SG11201702379TA (2)
WO (1)	WO2016046786A1 (2)
ZA (1)	ZA201702086B (2)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JO3387B1 (ar)	2011-12-16	2019-03-13	Glaxosmithkline Llc	مشتقات بيتولين
SG10201704467SA (en)	2012-12-14	2017-06-29	Glaxosmithkline Llc	Pharmaceutical compositions
EP3197430A1 (en)	2014-09-26	2017-08-02	Glaxosmithkline Intellectual Property (No. 2) Limited	Long acting pharmaceutical compositions
CA3005313C (en) *	2015-11-16	2024-01-09	Evonik Rohm Gmbh	Injection solution comprising a non-nucleoside reverse-transcriptase inhibitor and poly(lactide-co-glycolide)
CN107184551B (zh) *	2017-06-09	2020-09-01	甘肃新天马制药股份有限公司	一种利拉萘酯双粒径分布乳剂及其制备方法
US11564921B2 (en) *	2017-07-21	2023-01-31	Viiv Healthcare Company	Regimens for treating HIV infections and AIDS
JP7703538B2 (ja) *	2019-12-09	2025-07-07	ヴィーブ、ヘルスケア、カンパニー	カボテグラビルを含んでなる医薬組成物
CN118121552A (zh) *	2022-12-01	2024-06-04	浙江萃泽医药科技有限公司	一种可注射的药物组合物及其制备方法与应用

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB8815265D0 (en)	1988-06-27	1988-08-03	Wellcome Found	Therapeutic nucleosides
US5358721A (en)	1992-12-04	1994-10-25	Alza Corporation	Antiviral therapy
GB0004887D0 (en)	2000-03-01	2000-04-19	Astrazeneca Uk Ltd	Chemical compounds
EP1292562A1 (en)	2000-05-23	2003-03-19	Univerzita palackeho V Olomouci	Triterpenoid derivatives
DE10103810A1 (de)	2001-01-29	2002-08-01	Map Gmbh	Vorrichtung zur Zufuhr eines Atemgases
US7163700B2 (en)	2001-07-31	2007-01-16	Capricorn Pharma, Inc.	Amorphous drug beads
US8101629B2 (en)	2001-08-13	2012-01-24	Janssen Pharmaceutica N.V.	Salt of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino]benzonitrile
US7638522B2 (en)	2001-08-13	2009-12-29	Janssen Pharmaceutica N.V.	Salt of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino] benzonitrile
JO3429B1 (ar)	2001-08-13	2019-10-20	Janssen Pharmaceutica Nv	مشتقات برميدينات مثبطة فيروس الايدز
US20080206161A1 (en)	2002-10-25	2008-08-28	Dov Tamarkin	Quiescent foamable compositions, steroids, kits and uses thereof
US20050142205A1 (en)	2003-07-18	2005-06-30	Julia Rashba-Step	Methods for encapsulating small spherical particles prepared by controlled phase separation
WO2005112929A2 (en) *	2004-05-20	2005-12-01	Cornell Research Foundation, Inc.	Anti-hiv-1 activity of betulinol derivatives
US7150323B2 (en)	2004-07-26	2006-12-19	Vetco Gray Inc.	Shoulder ring set on casing hanger trip
TW200628161A (en)	2004-11-12	2006-08-16	Panacos Pharmaceuticals Inc	Novel betulin derivatives, preparation thereof and use thereof
EP1869063A2 (en)	2005-03-29	2007-12-26	Regents Of The University Of Minnesota	Methods of manufacturing bioactive 3-esters of betulinic aldehyde and betulinic acid
TW201414495A (zh) *	2005-04-04	2014-04-16	Tibotec Pharm Ltd	Ｈｉｖ-感染之預防
WO2006117666A2 (en)	2005-04-29	2006-11-09	Pfizer Inc.	Dosage forms, pharmaceutical compositions and methods for sub-tenon delivery
EP1986654A2 (en)	2006-02-21	2008-11-05	Achillion Pharmaceuticals, Inc.	Substituted taraxastanes useful for treating viral infections
FI121468B (fi)	2006-06-07	2010-11-30	Valtion Teknillinen	Betuliiniperäiset yhdisteet antimikrobisina aineina
CN101478950B (zh)	2006-06-23	2013-02-06	泰博特克药品有限公司	Tmc278的水性悬浮液
WO2008127364A2 (en)	2006-10-13	2008-10-23	Myriad Genetics, Inc.	Antiviral compounds and use thereof
CA2668452A1 (en)	2006-11-03	2008-05-15	Panacos Pharmaceuticals, Inc.	Extended triterpene derivatives
EP2240504A1 (en)	2008-01-03	2010-10-20	Virochem Pharma Inc.	Novel c-21-keto lupane derivatives preparation and use thereof
CA2711424A1 (en)	2008-01-03	2009-07-09	Virochem Pharma Inc.	Novel lupane derivatives
DE102008037025C5 (de)	2008-08-08	2016-07-07	Jesalis Pharma Gmbh	Verfahren zur Herstellung kristalliner Wirkstoff-Mikropartikel bzw. einer Wirkstoffpartikel-Festkörperform
WO2010053817A1 (en)	2008-11-04	2010-05-14	Trustees Of Dartmouth College	Betulinic acid derivatives and methods of use thereof
CZ301318B6 (cs)	2008-11-13	2010-01-13	Univerzita Palackého v Olomouci	2-Deoxyglykosidy triterpenoidu, zpusob jejich prípravy a jejich použití jako lécivo
KR101733625B1 (ko)	2008-12-11	2017-05-10	시오노기세야쿠 가부시키가이샤	카르바모일피리돈 ｈｉｖ 인테그라제 억제제 및 중간체의 합성
US8802727B2 (en)	2009-07-14	2014-08-12	Hetero Research Foundation, Hetero Drugs Limited	Pharmaceutically acceptable salts of betulinic acid derivatives
US9067966B2 (en)	2009-07-14	2015-06-30	Hetero Research Foundation, Hetero Drugs Ltd.	Lupeol-type triterpene derivatives as antivirals
US20110051713A1 (en)	2009-08-27	2011-03-03	Xerox Corporation	Facsimile prioritization within internet protocol call networks
WO2011100308A1 (en)	2010-02-11	2011-08-18	Glaxosmithkline Llc	Derivatives of betulin
TWI577377B (zh) *	2010-09-16	2017-04-11	Ｖｉｉｖ醫療保健公司	醫藥組合物
WO2013020246A1 (en)	2011-08-08	2013-02-14	Glaxosmithkline Llc	Methylene derivatives of betulin
WO2013020245A1 (en)	2011-08-08	2013-02-14	Glaxosmithkline Llc	Carbonyl derivatives of betulin
BR112014014046A2 (pt)	2011-12-14	2017-06-13	Glaxosmithkline Llc	composto, composição, e, método para tratar hiv
JO3387B1 (ar)	2011-12-16	2019-03-13	Glaxosmithkline Llc	مشتقات بيتولين
CN104844679B (zh)	2011-12-16	2017-03-01	葛兰素史克有限责任公司	白桦脂醇的衍生物
WO2014035945A1 (en)	2012-08-28	2014-03-06	Glaxosmithkline Llc	Pharmaceutical compositions
SG10201704467SA (en)	2012-12-14	2017-06-29	Glaxosmithkline Llc	Pharmaceutical compositions
EP3197430A1 (en)	2014-09-26	2017-08-02	Glaxosmithkline Intellectual Property (No. 2) Limited	Long acting pharmaceutical compositions

2015
- 2015-09-24 EP EP15775510.9A patent/EP3197430A1/en not_active Withdrawn
- 2015-09-24 MX MX2017003928A patent/MX2017003928A/es unknown
- 2015-09-24 EA EA201790495A patent/EA201790495A1/ru unknown
- 2015-09-24 CR CR20170113A patent/CR20170113A/es unknown
- 2015-09-24 SG SG11201702379TA patent/SG11201702379TA/en unknown
- 2015-09-24 BR BR112017006005A patent/BR112017006005A2/pt not_active Application Discontinuation
- 2015-09-24 PE PE2017000515A patent/PE20170691A1/es not_active Application Discontinuation
- 2015-09-24 KR KR1020177011108A patent/KR20170056702A/ko not_active Withdrawn
- 2015-09-24 CA CA2961528A patent/CA2961528A1/en not_active Abandoned
- 2015-09-24 CN CN201580062609.4A patent/CN106999425A/zh active Pending
- 2015-09-24 US US15/514,564 patent/US10092523B2/en not_active Expired - Fee Related
- 2015-09-24 JP JP2017516058A patent/JP2017528497A/ja not_active Withdrawn
- 2015-09-24 AU AU2015323321A patent/AU2015323321A1/en not_active Abandoned
- 2015-09-24 WO PCT/IB2015/057360 patent/WO2016046786A1/en not_active Ceased
2017
- 2017-03-22 IL IL251337A patent/IL251337A0/en unknown
- 2017-03-24 DO DO2017000086A patent/DOP2017000086A/es unknown
- 2017-03-24 CL CL2017000714A patent/CL2017000714A1/es unknown
- 2017-03-24 ZA ZA2017/02086A patent/ZA201702086B/en unknown

Also Published As

Publication number	Publication date
EA201790495A1 (ru)	2017-09-29
CR20170113A (es)	2017-05-26
DOP2017000086A (es)	2017-06-30
CN106999425A (zh)	2017-08-01
EP3197430A1 (en)	2017-08-02
ZA201702086B (en)	2019-06-26
KR20170056702A (ko)	2017-05-23
US10092523B2 (en)	2018-10-09
WO2016046786A1 (en)	2016-03-31
CL2017000714A1 (es)	2017-11-03
MX2017003928A (es)	2017-06-28
CA2961528A1 (en)	2016-03-31
IL251337A0 (en)	2017-05-29
US20170246118A1 (en)	2017-08-31
SG11201702379TA (en)	2017-04-27
BR112017006005A2 (pt)	2017-12-19
JP2017528497A (ja)	2017-09-28
AU2015323321A1 (en)	2017-04-13

Legal Events

Date	Code	Title	Description
2017-12-29	FA	Abandonment or withdrawal

Publication	Publication Date	Title
PE20170691A1 (es)	2017-06-13	Composiciones farmaceuticas de accion prolongada
PE20191815A1 (es)	2019-12-27	Formulaciones acuosas estables de adalimumab
MX2015015500A (es)	2016-08-11	Composiciones de cenicriviroc y metodos para elaborarlas y usarlas.
MX2022006940A (es)	2022-07-11	Composiciones farmaceuticas.
CO2017007293A2 (es)	2017-10-31	Dinucleótidos cíclicos útiles para el tratamiento de (inter alia) cáncer
GT201500088A (es)	2017-09-28	Derivados de 5-fenoxi-3h-pirimidin-4-ona y su uso como inhibidores de la transcriptasa inversa del vih
NI201800023A (es)	2018-06-12	Compuestos antivirales de fosfodiamida de éster de beta-aminoácido
MX2017002028A (es)	2017-08-14	Compuestos de pirrolopirimidina usados como agonista del receptor de tipo toll 7 (tlr7).
CL2017000287A1 (es)	2017-11-10	2-(morfolin-4-il)-1,7-naftiridinas.
CL2016000698A1 (es)	2016-09-23	Derivados de quinolizina sustituidos útiles como inhibidores de integrasa del vih
EA201691988A1 (ru)	2017-06-30	Производные бороновой кислоты и их терапевтическое применение
EA201692301A1 (ru)	2017-06-30	Производные бороновой кислоты и их терапевтическое применение
PE20141821A1 (es)	2014-11-24	Composiciones herbicidas que contienen bentazon y el inhibidor als y el inhibidor accasa
PE20090064A1 (es)	2009-03-02	Acido ribonucleico de doble cadena para inhibir la expresion del gen e6ap humano y composicion farmaceutica que lo comprende
CL2017002482A1 (es)	2018-04-20	Compuestos heterocíclicos y su uso en la prevención o tratamiento de las infecciones bacterianas
EA201590862A1 (ru)	2016-05-31	Фармацевтические композиции
DOP2016000253A (es)	2016-10-31	Nuevos compuestos
BR112017000246A2 (pt)	2018-03-27	composto, sal farmaceuticamente aceitável de um composto, composição farmacêutica, e, uso de um composto ou de um sal
CL2017002451A1 (es)	2018-04-20	Compuestos heterocíclicos novedosos y su uso en la prevención o tratamiento de las infecciones bacterianas
MX2016011358A (es)	2016-12-07	Composiciones liquidas de lactasa.
CL2017002803A1 (es)	2018-05-11	Compuestos heterocíclicos y su uso en la prevención o tratamiento de las infecciones bacterianas
DOP2016000007A (es)	2016-02-15	Pirazolpiridinas sustituidas
ECSP20007842A (es)	2020-09-30	Composiciones y métodos para formulaciones de alfavirus vivos atenuados
AR092691A1 (es)	2015-04-29	Composicion farmaceutica que comprende rebamipida
MX370990B (es)	2020-01-10	Ésteres de ácidos oligo-hidroxicarboxílicos y uso de los mismos.